Question · asked by 1 review
Pilocarpine lozenge (3 mg or 5 mg) vs placebo control: Dry mouth (xerostomia)
- Population
- Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's syndrome, radiotherapy, haemodialysis)
- Intervention
- Pilocarpine lozenge (3 mg or 5 mg)
- Comparison
- placebo control
- Outcome
- Dry mouth (xerostomia)
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Pilocarpine lozenge (3 mg or 5 mg) vs Placebo lozenge Xerostomia (oral dryness) · Adults seeking treatment for the symptom of dry mouth (xerostomia) due to any cause (e.g. medication, Sjogren's… · Single dose (up to 3 hours) Interventions for the management of dry mouth: topical therapies (2011) · Cochrane All outcomes | Taweechaisupapong 2006 (crossover): participants reported a statistically significant improvement in oral dryness after both 3 mg and 5 mg pilocarpine lozenges vs placebo (P <= 0.05); no usable data presented. No… | 1 study · 33 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for the management of dry mouth: topical therapies 2011 · Cochrane All outcomes | 2011-10 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.